HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Proportion of tadalafil-treated patients with clinically meaningful improvement in lower urinary tract symptoms associated with benign prostatic hyperplasia – integrated data from 1,499 study participants.

AbstractOBJECTIVES:
To evaluate the proportion of patients achieving clinically meaningful improvement of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH-LUTS) with tadalafil using two definitions of response.
PATIENTS AND METHODS:
Post hoc integrated analysis of four placebo-controlled studies in men (aged ≥45 years; International Prostate Symptom Score [IPSS] of ≥13; maximum urinary flow rate [Q(max)] of ≥4 to ≤15 mL/s) with BPH-LUTS randomised to tadalafil 5 mg (752 patients) or placebo (747) for 12 weeks after a 4-week placebo run-in. Responders were defined as having a total IPSS improvement of ≥3 points or ≥25% from randomisation to endpoint (Week 12). Response status was calculated per patient, and relative benefit and odds ratio (OR) with 95% confidence interval (CI) of tadalafil vs placebo was calculated using a logistic Generalised Mixed Model for Repeated Measures.
RESULTS:
Tadalafil 5 mg once daily resulted in a significantly greater proportion of patients achieving a ≥3-point IPSS improvement (71.1% and 56.0% for tadalafil and placebo patients, respectively [OR 1.9, 95% CI 1.5, 2.4; P < 0.001]) and achieving a ≥25% improvement in total IPSS randomisation to endpoint (61.7% and 45.5% for tadalafil and placebo patients, respectively [OR 2.0, 95% CI 1.6, 2.5; P < 0.001]).
CONCLUSION:
About two-thirds of tadalafil-treated patients achieve a clinically meaningful improvement in BPH-LUTS symptoms, based on two different definitions of responder status.
AuthorsJohn Curtis Nickel, Gerald B Brock, Sender Herschorn, Ruth Dickson, Carsten Henneges, Lars Viktrup
JournalBJU international (BJU Int) Vol. 115 Issue 5 Pg. 815-21 (May 2015) ISSN: 1464-410X [Electronic] England
PMID25195970 (Publication Type: Journal Article, Randomized Controlled Trial)
Copyright© 2014 The Authors. BJU International © 2014 BJU International.
Chemical References
  • Carbolines
  • Phosphodiesterase 5 Inhibitors
  • Tadalafil
Topics
  • Carbolines (therapeutic use)
  • Double-Blind Method
  • Humans
  • Lower Urinary Tract Symptoms (drug therapy, etiology)
  • Male
  • Middle Aged
  • Phosphodiesterase 5 Inhibitors (therapeutic use)
  • Prostatic Hyperplasia (complications)
  • Remission Induction
  • Tadalafil

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: